pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
Oct 13, 26
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs
endpoints
Oct 12, 26
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
biospace
Oct 12, 26
Tortugas’ schizophrenia drug proves worth in phase 2 Hansoh trial in China
fiercebiotech
Oct 12, 26
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
Oct 9, 26
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 8, 26
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
Oct 8, 26
STAT+: Roche goes beyond licensing in deal with Chinese biotech
stat
Oct 8, 26
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
Oct 8, 26
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
Oct 7, 26
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
Oct 7, 26
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 6, 26
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
fiercebiotech
Oct 6, 26
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
Oct 6, 26
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
Oct 6, 26
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 5, 26
Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears
endpoints
Oct 5, 26
Significant stock movers of September: Viking soars, Longeveron slides
biospace
Oct 5, 26
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
Oct 5, 26
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Oct 1, 26
BMS reports liver injury events in lung disease program, with key readout near
biospace
Oct 1, 26
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
Sep 30, 26
Patient death raises liver questions ahead of Bristol Myers readout
endpoints
← prev
page 4 of 12
next →